Related Experiment Videos
[Practical use of cefepime in an University hospital. Retrospective study of 35 cases]
A Gérard1, V Le Meins, P Maurer
1Service des Maladies Infecteuses et de Réanimation Neurorespiratoire, CHU Brabois, Vandoeuvre-les-Nancy, France.
Abstract:
The authors report a retrospective study of 35 patients treated with cefepime (Axepim). This patients were either hospitalized in a medical or in a surgical ICU or were febrile neutropenic patients. The non neutropenic group was put on cefepime for nosocomial pneumonia or miscellaneous sepsis. When recovered, Enterobacteriaceae were the most frequent pathogens. Clinical cure rate for the patients treated with cefepime was 83%. Cefepime is a safe and effective empirical treatment for serious infections and nosocomial infections in particular.
Insights
Cefepime (Axepim) demonstrated an 83% clinical cure rate in treating serious and nosocomial infections, including pneumonia and sepsis, in a study of 35 patients. This antibiotic is safe and effective for empirical treatment of severe bacterial infections.
Area of Science:
- Infectious Diseases
- Pharmacology
- Critical Care Medicine
Background:
- Nosocomial infections and sepsis pose significant treatment challenges, particularly in intensive care unit (ICU) patients and those with febrile neutropenia.
- Enterobacteriaceae are common pathogens in serious hospital-acquired infections.
Purpose of the Study:
- To evaluate the efficacy and safety of cefepime (Axepim) as an empirical treatment for serious infections.
- To assess cefepime's clinical cure rate in diverse patient populations, including ICU admissions and febrile neutropenic individuals.
Main Methods:
- A retrospective study was conducted on 35 patients treated with cefepime (Axepim).
- Patients included those hospitalized in medical or surgical ICUs, febrile neutropenic patients, and non-neutropenic patients with nosocomial pneumonia or sepsis.
Main Results:
- The overall clinical cure rate for patients treated with cefepime was 83%.
- Enterobacteriaceae were identified as the most frequent pathogens in recovered patients.
- Cefepime was found to be safe for empirical use.
Conclusions:
- Cefepime (Axepim) is a safe and effective empirical therapeutic option for serious and nosocomial infections.
- The study supports the use of cefepime in critical care settings and for febrile neutropenic patients.